Trump Administration Announces Tariffs on Patented Pharmaceuticals Under Section 232

April 2, 2026 — Washington, DC — The Trump administration has announced new tariffs on imported patented pharmaceutical products and their ingredients under Section 232 of the Trade Expansion Act of 1962, citing national security and supply chain considerations.¹

According to a White House fact sheet, the policy establishes a 100% tariff on patented pharmaceutical products and ingredients, with implementation timelines of 120 days for larger manufacturers and 180 days for smaller companies.¹

Policy Structure and Key Provisions

The tariff framework includes several conditional provisions and exemptions:

Baseline tariff:

• A 100% tariff applies to patented drugs and associated inputs.¹
• Trade agreement adjustments: Products imported from the European Union, Japan, South Korea, Switzerland, and Liechtenstein are subject to a 15% tariff, while products from the United Kingdom may be subject to a lower rate under a separate agreement.¹

Onshoring and pricing pathways:

• Companies that enter both most favored nation (MFN) pricing agreements with the Department of Health and Human Services (HHS) and onshoring agreements with the Department of Commerce may qualify for a 0% tariff through January 20, 2029.¹
• Companies that enter only onshoring agreements may be subject to a 20% tariff.¹

Exemptions:

• Generic drugs and biosimilars are not currently subject to tariffs, with reassessment planned in one year.¹
• Orphan drugs, animal health products, and certain specialty therapies may be exempt if they meet public health criteria or originate from specified trade partners.¹

Compliance measures:

• The policy includes monitoring mechanisms such as audits and provisions for tariff adjustments based on compliance.¹

National Security and Supply Chain Context

According to the administration, the tariffs follow an investigation by the Department of Commerce that concluded imports of certain pharmaceutical products and ingredients could affect US national security.¹

Section 232 of the Trade Expansion Act authorizes the federal government to impose trade restrictions when imports are determined to pose a national security risk and has previously been applied in sectors such as metals and manufacturing.²

Analyses of the pharmaceutical supply chain have found that the US relies on global sources for a portion of finished drugs and active pharmaceutical ingredients, which may present vulnerabilities during supply disruptions.²

Potential Industry and Market Considerations

The policy introduces several considerations for stakeholders across the healthcare system:

Manufacturing and investment:

The administration reports that anticipated tariffs have been associated with approximately $400 billion in investment commitments toward US-based pharmaceutical manufacturing.¹

Pricing dynamics: The inclusion of MFN pricing agreements is intended, according to the administration, to align US drug prices with those in other developed markets.¹

Supply chain adjustments: Manufacturers may evaluate sourcing, production, and distribution strategies in response to the policy.

Cost and access considerations: Some economic analyses suggest tariffs may affect costs depending on how manufacturers, payers, and other stakeholders respond.³

Broader Policy Context

The tariff announcement follows prior executive actions focused on pharmaceutical manufacturing and supply chain resilience, including initiatives to reduce regulatory barriers to domestic production and to establish reserves of key pharmaceutical ingredients.¹

Additional reporting indicates the policy may also influence company decisions related to US manufacturing and pricing strategies.⁴

Some stakeholders, including economists and industry analysts, have noted that trade measures in the pharmaceutical sector may have implications for investment, innovation, and patient access, depending on how policies are implemented and how the market responds.⁵

Key Takeaways

• The Trump administration announced 100% tariffs on patented pharmaceuticals under Section 232, citing national security and supply chain considerations.¹
• Reduced or zero tariff pathways are available for companies that enter US manufacturing and/or pricing agreements with federal agencies.¹
• Generic drugs, biosimilars, and certain specialty products are currently exempt, with future reassessment planned.¹
• The policy is part of broader federal efforts related to domestic pharmaceutical manufacturing and supply chain resilience.¹
• Potential impacts on pricing, investment, and access remain dependent on industry response and policy implementation.³⁻⁵

References

1. The White House. Fact Sheet: President Donald J. Trump bolsters national security and strengthens U.S. supply chains by imposing tariffs on patented pharmaceutical products. Published April 2, 2026. Accessed April 2, 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
2. Ernst & Young. Why the Trump pharma import inquiry is pivotal. Accessed April 2, 2026. https://www.ey.com/en_us/insights/life-sciences/why-the-trump-pharma-import-inquiry-is-pivotal Tax Foundation.
3. Pharmaceutical tariffs and economic impact. Accessed April 2, 2026. https://taxfoundation.org/blog/pharmaceutical-tariffs/
4. Axios. Trump targets drug prices with new tariff policy. April 2, 2026. Accessed April 2, 2026. https://www.axios.com/2026/04/02/trump-drug-prices-tariffs
5. The Washington Post. Tariffs on pharmaceuticals raise questions for costs and innovation. April 2, 2026. Accessed April 2, 2026. https://www.washingtonpost.com/business/2026/04/02/tariffs-drugs-pharma-trump/